Evidence doesn't support coverage for 2 incontinence treatments, says panel

Why This Topic Matters

Coverage decisions for urinary incontinence therapies can affect payer policy, provider reimbursement, and whether specific services are reimbursed under Medicare or left to carrier discretion. The article helps coding and reimbursement professionals understand the policy context behind these treatments and the evidence standards influencing coverage recommendations.

Article Sections

1. Medicare panel review of urinary incontinence therapies

   Introduces the advisory panel’s evidence review and the broader Medicare policy context. Summarizes the treatment categories under review and the role of the committee in coverage recommendations.

2. Evidence standards and panel discussion

   Describes how the panel applied its evidence rules during deliberations. Notes concerns raised about the strictness of the standards and the process used for recommendations.

3. Future coverage consideration

   Mentions an additional urinary incontinence therapy scheduled for later review. Places the current discussion in the context of upcoming committee activity.